Fougner C, et al. Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020;11(1):1787.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Voutsadakis IA. Comparison of clinical subtypes of breast cancer within the claudin-low molecular cluster reveals distinct phenotypes. Cancers(Basel). 2023;15(10):2689.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan C, et al. Research progress of claudin-low breast cancer. Front Oncol. 2023;13:1226118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dominguez C, et al. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight. 2017. https://doi.org/10.1172/jci.insight.94296.

Article  PubMed  PubMed Central  Google Scholar 

Knezevic J, et al. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene. 2015;34(49):5997–6006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rädler PD, et al. Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. Nat Commun. 2021;12(1):3742.

Article  PubMed  PubMed Central  Google Scholar 

Pommier RM, et al. Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. Nat Commun. 2020;11(1):3431.

Article  PubMed  PubMed Central  Google Scholar 

Yadav R, et al. Claudins: the newly emerging targets in breast cancer. Clin Breast Cancer. 2022;22(8):737–52.

Article  CAS  PubMed  Google Scholar 

Tabariès S, Siegel PM. The role of claudins in cancer metastasis. Oncogene. 2017;36(9):1176–90.

Article  PubMed  Google Scholar 

Li J. Targeting claudins in cancer: diagnosis, prognosis and therapy. Am J Cancer Res. 2021;11(7):3406–24.

CAS  PubMed  PubMed Central  Google Scholar 

Wang DW, et al. The role and mechanism of claudins in cancer. Front Oncol. 2022;12:1051497.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yousefi H, et al. Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer. BMC Cancer. 2022;22(1):1282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nandi A, Chakrabarti R. The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance. Genes Dev. 2020;34(21–22):1422–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Totaro A, et al. Crosstalk between YAP/TAZ and Notch signaling. Trends Cell Biol. 2018;28(7):560–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bray SJ, Bigas A. Modes of Notch signalling in development and disease. Nat Rev Mol Cell Biol. 2025;26(7):522–37.

Article  CAS  PubMed  Google Scholar 

Liu Y, et al. Notch pathway deactivation sensitizes breast cancer stem cells toward chemotherapy using NIR light-responsive nanoparticles. ACS Appl Mater Interfaces. 2025;17(1):430–44.

Article  CAS  PubMed  Google Scholar 

Majumder S, et al. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov. 2021;20(2):125–44.

Article  CAS  PubMed  Google Scholar 

McCaw TR, et al. Gamma Secretase inhibitors in cancer: a current perspective on clinical performance. Oncologist. 2021;26(4):e608–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yadav R, et al. Comparative morphology of tumour microenvironment in claudin-low and claudin-high breast cancers. Pathol Res Pract. 2024;261:155502.

Article  CAS  PubMed  Google Scholar 

Mima S, et al. Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Res. 2005;65(5):1868–76.

Article  CAS  PubMed  Google Scholar 

Mei H, et al. Doxorubicin activates the Notch signaling pathway in osteosarcoma. Oncol Lett. 2015;9(6):2905–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dias K, et al. Claudin-low breast cancer; clinical & pathological characteristics. PLoS ONE. 2017;12(1):e0168669.

Article  PubMed  PubMed Central  Google Scholar 

Haughian JM, et al. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A. 2012;109(8):2742–7.

Article  CAS  PubMed  Google Scholar 

Wang K, et al. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in Triple-Negative Breast Cancer sensitive to a γ-Secretase inhibitor. Clin Cancer Res. 2015;21(6):1487–96.

Article  PubMed  Google Scholar 

Dickson BC, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol. 2007;20(6):685–93.

Article  CAS  PubMed  Google Scholar 

Zhang Y-Q, et al. Notch3 inhibits cell proliferation and tumorigenesis and predicts better prognosis in breast cancer through transactivating PTEN. Cell Death Dis. 2021;12(6):502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin H-Y, et al. Notch3 inhibits epithelial–mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 2018;7(8):59.

Article  PubMed  PubMed Central  Google Scholar 

Dou XW, et al. Notch3 maintains luminal phenotype and suppresses tumorigenesis and metastasis of breast cancer via trans-activating estrogen receptor-α. Theranostics. 2017;7(16):4041–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diluvio G, et al. NOTCH3 inactivation increases triple-negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. Oncogenesis. 2018;7(5):42.

Article  PubMed  PubMed Central  Google Scholar 

Choy L, et al. Constitutive NOTCH3 signaling promotes the growth of basal breast cancers. Cancer Res. 2017;77(6):1439–52.

Article  CAS  PubMed  Google Scholar 

BeLow M, Osipo C. Notch signaling in breast cancer: a role in drug resistance. Cells. 2020. https://doi.org/10.3390/cells9102204.

Article  PubMed